Insider Transactions Reported by 28 Insiders of Carisma Therapeutics Inc.

Symbol: CARM on OTC
Location: Philadelphia, PA

Quick Takeaways

CARM - Carisma Therapeutics Inc. has 28 insiders with reported activity on this page.
Net insider value flow over the last year: -$138,828.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: ; sell value: $138,827.
Net share flow: -541,329.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$138,828.

Buys

Shares: 0

Insiders: 0

Sells

$138,828

Shares: 541,329

Insiders: 1

Net

-$138,828

Shares: -541,329

Insiders: -1

Window (months)	Sell shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	0	$0	$0	$0
6-9	541,329	$0	$138,828	-$138,828
9-12	0	$0	$0	$0

Carisma Therapeutics Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
ModernaTX, Inc.	10%+ Owner	$2,969,831			Mixed	07 Mar 2023
Regina Hodits	Director	$1,348,660			Mixed	07 Mar 2023
Thomas R. Cannell	President and CEO, Director	$394,691			Filing P/S	02 Mar 2023
Minori Rosales	Chief Development Officer	$365,701			Mixed	24 Jan 2022
Monica Forbes	Chief Financial Officer	$296,825			Filing P/S	02 Mar 2023
Glen C. MacDonald	Chief Technology Officer	$234,165			Filing P/S	02 Mar 2023
Mark Sullivan	General Counsel & Secretary	$222,268			Filing P/S	02 Mar 2023
Elly Ryu	Principal Accounting Officer	$87,242			Filing P/S	02 Mar 2023
Peter Honig	Director	$23,480			Mixed	22 Jun 2022
Carrie L. Bourdow	Director	$23,480			Mixed	22 Jun 2022
Michael A. S. Jewett	Director	$23,480			Mixed	22 Jun 2022
Jason A. Keyes	Director	$23,480			Mixed	22 Jun 2022
Jay S. Duker	Director	$23,480			Mixed	22 Jun 2022
Michael Klichinsky	Chief Scientific Officer	$0	-$138,828	-100%	Mixed	07 Oct 2025
Bjorn Odlander	Director				Mixed	07 Mar 2023
John Hohneker	Director				Mixed	26 Jun 2024
Natalie McAndrew	Vice President of Finance				Mixed	01 Jan 2025
Marella Thorell	Director				Mixed	01 Jul 2024
Sohanya Roshan Cheng	Director				Mixed	31 Oct 2024
Steven Kelly	President and CEO, Director				Mixed	28 Jan 2025
Briggs Morrison	Director				Mixed	26 Jun 2024
Michael Torok	Director				Mixed	26 Jun 2024
Chidozie Ugwumba	Director				Mixed	06 Jun 2023
Sanford S. Zweifach	Director				Mixed	26 Jun 2024
Richard Steven Morris	Chief Financial Officer				Mixed	17 Jun 2024
David Scadden	Director				Mixed	01 Jul 2024
Patricia M. Drake	Chief Commercial Officer				Mixed	01 Jun 2021
Jane Pritchett Henderson	Director				Mixed	03 May 2021

Top shareholders of Carisma Therapeutics Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ModernaTX, Inc.	3/4/5	10%+ Owner	— class O/S missing	5,059,338	$2,969,831	—	07 Mar 2023	3/4/5
Regina Hodits	3/4/5	Director	— class O/S missing	2,297,546	$1,348,660	—	07 Mar 2023	3/4/5
AbbVie Biotechnology Ltd	13D/G	—	4.4%	1,855,871	$408,292	$0	31 Mar 2025	13D/G
Thomas R. Cannell	3/4/5	President and CEO, Director	— class O/S missing	672,386	$394,691	—	02 Mar 2023	3/4/5
Minori Rosales	3/4/5	Chief Development Officer	— class O/S missing	623,000	$365,701	—	24 Jan 2022	3/4/5
Monica Forbes	3/4/5	Chief Financial Officer	— class O/S missing	505,664	$296,825	—	02 Mar 2023	3/4/5
Glen C. MacDonald	3/4/5	Chief Technology Officer	— class O/S missing	398,918	$234,165	—	02 Mar 2023	3/4/5
Mark Sullivan	3/4/5	General Counsel & Secretary	— class O/S missing	378,651	$222,268	—	02 Mar 2023	3/4/5
Elly Ryu	3/4/5	Principal Accounting Officer	— class O/S missing	148,624	$87,242	—	02 Mar 2023	3/4/5
Merck & Co., Inc.	13F	Company	3.5%	1,473,240	$63,349	—	31 Dec 2025	13F
Carrie L. Bourdow	3/4/5	Director	— mixed-class rows	105,000 mixed-class rows	$23,480	—	22 Jun 2022	3/4/5
Jason A. Keyes	3/4/5	Director	— mixed-class rows	105,000 mixed-class rows	$23,480	—	22 Jun 2022	3/4/5
Jay S. Duker	3/4/5	Director	— mixed-class rows	105,000 mixed-class rows	$23,480	—	22 Jun 2022	3/4/5
Michael A. S. Jewett	3/4/5	Director	— mixed-class rows	105,000 mixed-class rows	$23,480	—	22 Jun 2022	3/4/5
Peter Honig	3/4/5	Director	— mixed-class rows	105,000 mixed-class rows	$23,480	—	22 Jun 2022	3/4/5
XTX Topco Ltd	13F	Company	0.1%	40,097	$1,724	—	31 Dec 2025	13F
Empowered Funds, LLC	13F	Company	0.07%	30,988	$1,332	—	31 Dec 2025	13F
Baader Bank Aktiengesellschaft	13F	Company	0.05%	19,515	$517	—	31 Dec 2025	13F
Union Bancaire Privee, UBP SA	13F	Company	0%	785	$28	—	31 Dec 2025	13F
IFP Advisors, Inc	13F	Company	0%	206	$9	—	31 Dec 2025	13F
ORG Partners LLC	13F	Company	0%	200	$8	—	31 Dec 2025	13F
Patricia M. Drake	3/4/5	Chief Commercial Officer	— class O/S missing	1,000,000	—	—	01 Jun 2021	3/4/5
Steven Kelly	3/4/5	President and CEO, Director	— class O/S missing	500,000	—	—	28 Jan 2025	3/4/5
Jane Pritchett Henderson	3/4/5	Director	— class O/S missing	92,500	—	—	03 May 2021	3/4/5
Richard Steven Morris	3/4/5	Chief Financial Officer	— class O/S missing	85,000	—	—	17 Jun 2024	3/4/5
Chidozie Ugwumba	3/4/5	Director	— class O/S missing	38,700	—	—	06 Jun 2023	3/4/5
David Scadden	3/4/5	Director	— class O/S missing	38,700	—	—	01 Jul 2024	3/4/5
Marella Thorell	3/4/5	Director	— class O/S missing	38,700	—	—	01 Jul 2024	3/4/5
Sohanya Roshan Cheng	3/4/5	Director	— class O/S missing	38,700	—	—	31 Oct 2024	3/4/5
Briggs Morrison	3/4/5	Director	— class O/S missing	19,350	—	—	26 Jun 2024	3/4/5
John Hohneker	3/4/5	Director	— class O/S missing	19,350	—	—	26 Jun 2024	3/4/5
Michael Torok	3/4/5	Director	— class O/S missing	19,350	—	—	26 Jun 2024	3/4/5
Sanford S. Zweifach	3/4/5	Director	— class O/S missing	19,350	—	—	26 Jun 2024	3/4/5

Recent Insider Transactions by Companies or Individuals for Carisma Therapeutics Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Michael Klichinsky	CARM	Common Stock	Sale	-100%	$14,485	$0.2542	-56,982	0	07 Oct 2025	Direct
Michael Klichinsky	CARM	Common Stock	Options Exercise				56,982	56,982	07 Oct 2025	Direct
Michael Klichinsky	CARM	Stock Option (right to buy)	Options Exercise	-100%			-56,982	0	07 Oct 2025	Direct
Michael Klichinsky	CARM	Common Stock	Sale	-100%	$31,078	$0.2604	-119,347	0	03 Oct 2025	Direct
Michael Klichinsky	CARM	Common Stock	Sale	-62.6%	$50,860	$0.2543	-200,000	119,347	02 Oct 2025	Direct
Michael Klichinsky	CARM	Common Stock	Sale	-34.1%	$42,405	$0.2570	-165,000	319,347	01 Oct 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.